2、百奥赛图(北京)医药科技股份有限公司于2025-12-10上市，公司主营业务为从事提供基因编辑服务、 临床前药理药效评估服务、模式动物销售、抗体开发及创新药开发。 3、百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司 通过五个分部开展业务。 来源：新浪证券-红岸工作室 2月26日，百奥赛图涨8.15%，成交额2.11亿元，换手率7.92%，总市值346.39亿元。 异动分析 AI智能体+科创次新股+CRO概念+人民币贬值受益+注册制次新股 1、2026年1月13日互动易：我们通过AI的本地化部署，正在建设抗体药物研发AI智能体。随着千鼠万 抗计划与AI系统深度整合的持续推进，我们将为全球药企提供更加高效的研发工具和更为丰富的抗体 分子库，帮助药企伙伴提高临床前PCC分子的研发效率，这也将推动抗体发现业务迈入全新发展阶段。 区间今日近3日近5日近10日近20日主力净流入218.42万-921.89万-975.39万2306.19万7132.04万 公司简介 4、根据2024年年报，公司海外营收占比为67.94%，受益于人民币贬值。 5、百奥赛图(北京)医药科技股份有限 ...

产品主要在境内销售 信得科技成立于1999年，是中国一家动物保健企业，其主要从事全系列动物保健及配套产品的研发、生 产及销售，产品涵盖兽用生物制品(如疫苗、抗体、转移因子等)、中兽药、化药制剂、动物饲料及饲料 添加剂，实现对家禽、家畜、水产动物及宠物疾病的预防、诊断、治疗与控制。 招股书援引灼识咨询的资料称，以2024年收入计，信得科技是在中国动物保健市场中排名第九的国产品 牌厂商，并在中国禽用兽用生物制品市场排名前三。虽然在国内排名靠前，但灼识咨询的资料显示，目 前中国有超过1500家兽药生产商，动物保健行业面临激烈的竞争。 信得科技坦言："我们的客户在兽用生物制品及药物采购方面的议价能力提升，因此，我们的客户可能 会通过谈判达成对我们较为不利的条款，这可能会降低我们的盈利能力。超出我们控制范围的因素可能 会导致我们的收入或盈利能力下降。" 《每日经济新闻》记者注意到，截至2025年三季度末，信得科技拥有4大生产基地、34条通过兽药 GMP(药品生产质量管理规范)验证的生产线。信得科技的商业模式聚焦两大核心动力：为客户提供精准 防控解决方案以及通过创新与生产提供高质量及成本效益的产品。 按产品划分，2023 ...

据港交所官网，山东信得科技股份有限公司（以下简称"信得科技"）日前首次向港交所呈交了IPO（首次公开募股）申请文件，工 银国际和中泰国际为联席保荐人。据招股书（申请版本，下同），信得科技拟将此次港股IPO募集资金用于研发计划及扩展产品组 合、扩大产能、拓展海外市场以及营运资金及其他一般公司用途。 《每日经济新闻》记者（以下简称"每经记者"）注意到，尽管信得科技称其在中国动物保健市场中排名靠前，但该行业面临激烈 的竞争，且客户在兽用生物制品及药物采购方面的议价能力提升，或影响其盈利能力。此外，信得科技在2024年因抗体产品的平 均售价下降导致收入和利润"双降"。值得一提的是，信得科技的估值在C轮融资过后达到约18亿元，但较B轮融资及于2022年8月进 行的股份转让后的约28.78亿元的估值缩水了近四成。 客户议价能力提升或降低公司盈利能力 信得科技成立于1999年，是中国一家动物保健企业，其主要从事全系列动物保健及配套产品的研发、生产及销售，产品涵盖兽用 生物制品（如疫苗、抗体、转移因子等）、中兽药、化药制剂、动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾 病的预防、诊断、治疗与控制。 招股书援引灼识 ...

动物保健行业头部企业，中国禽用兽用生物制品排名第三的供应商，2025年收入利润双增的信得科技赴港上市。 智通财经APP了解到，近日信得科技向港交所主板递交上市申请书，工银国际、中泰国际为其联席保荐人。该公司是中国领先的动物保健企业，根据灼识咨 询的资料，以2024年收入计，该公司以1.4%的市场份额在中国动物保健市场中排名第九，并以7.9%的市场份额在中国禽用兽用生物制品市场排名前三。 信得科技主要从事全系列动物保健及配套产品的研发、生产及销售，旗下有20家子公司，其中旗下5家子公司在经营中作出重大贡献，分别是北京信得、山 东海利、青岛信得、山东信得及青岛幸福。在业绩上，2024年及2025年前九月，收入分别增长-0.3%及25.2%，盈利能力较低，净利率分别为2.8%及6.3%。 动物保健市场规模增长较缓，根据灼识咨询，2024年全球动物保健行业市场规模511亿美元（按即时汇率为3525.9亿元人民币），近五年复合增速仅为 4.9%，中国市场规模为680亿元，复合增长仅为6%。行业前景一般，但该公司积极扩张全球市场，截止2025年9月，该公司拥有现金及等价物1.37亿元。 图片来源：公司聆讯资料 信得科技通 ...

来源：智通财经 文 | 周涛 山东宠物经济或再壮大。 2026年2月16日，一家来自山东潍坊诸城的"隐形冠军"企业——山东信得科技股份有限公司，向香港联 合交易所递交了主板上市申请，为自己的资本市场之旅按下了启动键。 图片来源：港交所 根据灼识咨询的报告，以2024年收入计，信得科技在中国动物保健市场的国产厂商中排名第九，市场份 额约为1.4%。 然而，其真正的核心竞争力体现在更为细分的领域：在中国禽用兽用生物制品市场，公司稳居前三。 | 量纂]的[编纂]數目 : [編纂]股H股(視乎[編纂] | | | | --- | --- | --- | | 行使與否而定) | | | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]) | | [編纂]數目 | . . | [編纂]股H股(可予[編纂]及視乎[編纂] | | 行使與否而定) | | | | 最高[編纂] | .. | 每股H股[編纂]港元,另加1.0%經紀 | | 佣金、0.0027%證監會交易徵費、 | | | | 0.00015%會財局交易徵費及0.00565% | | | | 香港聯交所交易費(須於[編纂]時以港 | | | | 元繳 ...

Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, with ICBC International and Zhongtai International as joint sponsors [1] Company Overview - Established in 1999 and located in Weifang, Shandong, Xinde Technology is a leading animal health enterprise in China, focusing on the R&D, production, and sales of a full range of animal health products [3] - The product matrix includes veterinary biological products (vaccines, antibodies, transfer factors), traditional Chinese veterinary medicine, chemical drug formulations, feed, and feed additives, catering to the health management needs of poultry, livestock, aquatic animals, and pets [3] - The company has been recognized as a national enterprise technology center, a high-tech enterprise, and a specialized and innovative small giant enterprise by the Ministry of Industry and Information Technology [3] Market Position - According to ZhiShi Consulting, Xinde Technology ranks 9th among domestic manufacturers in China's animal health market with a market share of approximately 1.4% as of 2024, and it is among the top three in the poultry veterinary biological products market [3] - The company holds the leading market share in specific segments such as veterinary transfer factors, Newcastle disease vaccines, and avian mycoplasma vaccines [3] Technological Innovation - Xinde Technology emphasizes technological innovation, holding 12 national-level new veterinary drug approvals, 25 biological product approvals, and 21 traditional Chinese veterinary medicine approvals [5] - It is one of the first companies globally to use suspension culture technology for producing highly pathogenic avian influenza vaccines and has launched the first quadrivalent poultry vaccine in China [5] Production Capacity - The company has established four production bases in Shandong and Beijing, equipped with 34 production lines certified by the new veterinary drug GMP standards, and has invested 1.1 billion yuan in advanced manufacturing capacity [5] Financial Performance - The unaudited financial data shows that Xinde Technology achieved revenues of 985 million yuan, 982 million yuan, and 877 million yuan for the years 2023, 2024, and the first nine months of 2025, respectively [5] - Gross profits for the same periods were 456 million yuan, 452 million yuan, and 436 million yuan, with gross margins of 49.7%, 50.8%, and 55.3% [5] - The net profits for these periods were 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan, indicating a steady improvement [5] International Expansion - Xinde Technology's overseas revenues were 12.2 million yuan, 28.3 million yuan, and 46.1 million yuan for the same periods, showing rapid growth, with products entering markets in Pakistan, Egypt, and Vietnam [5] - The company is also working on distributor registrations in 31 countries [5] Shareholding and Management - As of February 7, the controlling shareholder is the company's chairman and president, Li Chaoyang, who holds 45.08% of the voting rights [6] - Sumitomo Corporation, a Fortune Global 500 company, is a strategic shareholder [6] Industry Environment - The Chinese animal health industry is currently experiencing a dual track of policy tightening and market expansion, with the implementation of new veterinary drug GMP certifications accelerating industry reshuffling [6] - The market size for China's animal health sector is projected to reach 68 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.0% from 2019 to 2024, and expected to grow to 141 billion yuan by 2034 [6] - The global animal health market is estimated to be approximately 51.1 billion USD in 2024, with projections of reaching 85.8 billion USD by 2034 [6] Fundraising Purpose - Although specific amounts are not disclosed, the funds raised from the IPO will primarily be used to expand production bases and capacity, enhance R&D in new vaccines, chemical drugs, and pet medicines, and expand domestic and international sales networks [6] - The company aims to deepen its integrated development model of "mineral + energy," consolidate its domestic market advantage, accelerate overseas market penetration, and seize opportunities in emerging sectors such as pet economy and antibiotic-free farming [6]

Group 1 - The core viewpoint of the article is that Shandong Xinde Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to expand its presence in the animal health market [1] - Shandong Xinde Technology was established in 1999 and is recognized as a leading animal health company in China [1] - The company engages in the research, production, and sales of a full range of animal health products, including veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [1] Group 2 - According to the prospectus, Shandong Xinde Technology ranks ninth among domestic manufacturers in the Chinese animal health market based on projected revenue for 2024 [1] - The company is also ranked among the top three in the Chinese veterinary biological products market for poultry [1]

Company Overview - Shandong Xinde Technology Co., Ltd. is a leading animal health enterprise in China, established in 1999, focusing on the research, production, and sales of a full range of animal health products [3] - The company ranks ninth among domestic manufacturers in the Chinese animal health market, with a market share of 1.4% as of 2024 [4][12] - Its product offerings include veterinary biological products, traditional Chinese veterinary medicine, chemical drug formulations, animal feed, and feed additives [3] Business Model - The company operates on two core drivers: providing precise prevention and control solutions and leveraging innovation and production capabilities to deliver high-quality, cost-effective products [3][5] - It has established four production bases and 34 production lines certified by the new veterinary drug GMP [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately RMB 985 million, RMB 982 million, and RMB 878 million, respectively [6] - The net profit for the same periods was RMB 34.76 million, RMB 28.12 million, and RMB 55.67 million, respectively [7] - The gross profit margin improved from 49.7% in 2023 to 55.3% in 2025 [8] Industry Overview - The global animal health market was valued at USD 40.2 billion in 2019 and is projected to grow to USD 51.1 billion by 2024, with a CAGR of 4.9% [11] - The Chinese animal health market is expected to grow from RMB 509 billion in 2019 to RMB 680 billion by 2024, with a CAGR of 6.0% [12] Market Drivers - The increasing difficulty in animal disease prevention and control due to globalization and cross-border logistics has heightened the demand for effective animal health solutions [16] - The trend towards large-scale farming is evident, with the proportion of large-scale pig farming in China expected to rise from 50% in 2019 to 70% by 2024 [16] - There is a growing demand for pet health care driven by the increasing number of single-person households and an aging population in China [17]

Core Viewpoint - The company, a global provider of life science tools and technology services, is set to go public on the Hong Kong Stock Exchange, having previously listed on the A-share market in 2021, with a current market capitalization of approximately 11.6 billion RMB [1]. Financial Performance - The company reported revenues of 645 million RMB and a net profit of 120 million RMB for 2024, with a gross margin of 84.77% [1]. - For the first nine months of 2025, the company achieved revenues of 613 million RMB and a net profit of 132 million RMB, reflecting a year-on-year revenue growth of 32.26% and a net profit growth of 66.66% [5]. - The gross margin for the first nine months of 2025 was 82.20%, while the net profit margin was 21.48% [5]. Market Position - According to Frost & Sullivan, the company ranks first among all domestic suppliers in China and third globally in the recombinant protein market, with a market share of approximately 2.5% [9][10]. - The global recombinant protein market is projected to grow from 1 billion USD in 2020 to 3 billion USD by 2024, with a compound annual growth rate (CAGR) of 31.9% [6]. Product and Service Offering - The company offers a comprehensive product portfolio that includes high-quality biological reagents, such as recombinant proteins, antibodies, and analytical test kits, along with various technical services [2]. - As of the latest date, the company provides over 5,000 product SKUs and diverse technical service combinations, all produced under strict international quality standards [2]. Client Base and Business Model - The company serves a diverse and high-quality client base, including major pharmaceutical companies and high-growth biotech firms, with a 100% repurchase rate from its top 20 clients [4]. - The company operates on a "dual-engine" business model in both China and the United States, providing lifecycle solutions across research, production, and clinical application stages [4]. Industry Overview - The recombinant protein market in China is expected to expand from 100 million USD in 2020 to 400 million USD by 2024, with a CAGR of 25.9% [6].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively developing products related to monkeypox and has a strong focus on recombinant proteins and cell immunotherapy, benefiting from the depreciation of the RMB and being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Performance - As of September 30, 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, with a year-on-year increase of 58.61% [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. - The main business revenue composition includes 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [8]. Group 2: Market Position and Recognition - The company has been included in the Ministry of Industry and Information Technology's list of national "specialized, refined, distinctive, and innovative" small giant enterprises, which signifies its strong innovation capability and market share in niche markets [3]. - The company is involved in various concept sectors, including monkeypox, Alzheimer's, cell immunotherapy, biomedicine, and artificial intelligence [9]. Group 3: Stock Performance and Trading Activity - On February 12, the company's stock rose by 0.94%, with a trading volume of 311 million yuan and a turnover rate of 4.78%, leading to a total market capitalization of 8.476 billion yuan [1]. - The average trading cost of the stock is 56.87 yuan, with recent buying activity observed, although the buying strength is not strong [7]. - The stock has a significant number of shareholders, totaling 10,600, with a decrease of 9.75% compared to the previous period [9].